Kardigan, Inc. (KARD) company profile
KARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$13.19+0.34 (+2.65%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
About Kardigan
Pharmaceutical Preparations, SIC 2834
Kardigan, Inc. is listed on Nasdaq under the ticker KARD, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Kardigan, Inc.
- Headquarters
- South San Francisco, CA
- Address
- C/O Kardigan, Inc., 131 Oyster Point Blvd., Second Floor 94080
- Phone
- (415) 573-3220
- Website
- kardigan.bio
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- KARD
- Exchange
- Nasdaq
- IPO date
- Jun 18, 2026
- Shares outstanding
- 94M, Aug 7, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2123613
- CUSIP
- 48563V117
- ISIN
- US48563V1171
- FIGI
- BBG01T3TSSM2
- Share class FIGI
- BBG01T3TSSN1
- EIN
- 93-2994203
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Anastasios Gianakakos | President & CEO, Director | 9,806,633 |
| John B. Moriarty | Chief Legal Officer | 47,784 |
| Jay Edelberg | Chief Medical Officer | 4,595,383 |
| Andy Pasternak | Chief Strategy Officer | 79,640 |
| Brianne Jahn | Chief Financial Officer | 79,640 |
| Kristin Marie K. Reinke | Director | – |
| Advisors Llc Perceptive | Director | – |
| Capital Solutions Holdings LP Perceptive | Director | – |
| Joseph Edelman | Director | 20,706 |
| Life Sciences Master Fund Ltd Perceptive | Director | – |
| Kristina Burow | Director | – |
| Paul L. Berns | Director | 15,062,741 |
| Steven Gillis | Director | – |
| ARCH Venture Partners XIII, LLC | Director | – |
| ARCH Venture Fund XIII, L.P. | Director | – |
| ARCH Venture Partners XIII, L.P. | Director | – |
| Keith Crandell | Director | – |
| Robert Nelsen | Director | 15,042,035 |
| David P. Meeker | Director | 20,706 |
| Kimberly J. Popovits | Director | 20,706 |
| Douglas E. Giordano | Director | 20,706 |
| Timothy P. Walbert | Director | 20,706 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 18, 2026
- Offer price
- $16.00
- Securities offered
- 25,000,000
- Gross proceeds
- $400.00M
- Exchange
- Nasdaq
- First trading day
- Jun 18, 2026
- First-day close
- $22.00+37.5%
- Lock-up ends (est.)
- Dec 15, 2026
“The initial public offering price per share is $16.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 18, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 15, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?